Accessorized DPI: a Shortcut towards Flexibility and Patient Adaptability in Dry Powder Inhalation

Buttini, Francesca; Hannon, James C.; Saavedra, Kristi; Rossi, Irene; Balducci, Anna; Clark, Andrew R.; Colombo, Paolo

doi:10.1007/s11095-016-2023-0

Cited by 12 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results suggest as well that there was low cohesion among microparticles, which led to high deaggregation during aerosolisation and in agreement with the in vitro respirability usually exhibited by DPI formulation [24]. Additionally, the use of the RS01 device may have contributed to the maximisation of the performance, as it is described that the spinning capsule rotation provided by this inhaler is more efficient compared with the other capsule motion in the powder deaggregation [30,31].…”

Section: Resultssupporting

confidence: 57%

Inhalable Fucoidan Microparticles Combining Two Antitubercular Drugs with Potential Application in Pulmonary Tuberculosis Therapy

et al. 2018

Self Cite

View full text Add to dashboard Cite

The pulmonary delivery of antitubercular drugs is a promising approach to treat lung tuberculosis. This strategy not only allows targeting the infected organ instantly, it can also reduce the systemic adverse effects of the antibiotics. In light of that, this work aimed at producing fucoidan-based inhalable microparticles that are able to associate a combination of two first-line antitubercular drugs in a single formulation. Fucoidan is a polysaccharide composed of chemical units that have been reported to be specifically recognised by alveolar macrophages (the hosts of Mycobacterium ). Inhalable fucoidan microparticles were successfully produced, effectively associating isoniazid (97%) and rifabutin (95%) simultaneously. Furthermore, the produced microparticles presented adequate aerodynamic properties for pulmonary delivery with potential to reach the respiratory zone, with a mass median aerodynamic diameter (MMAD) between 3.6–3.9 µm. The formulation evidenced no cytotoxic effects on lung epithelial cells (A549), although mild toxicity was observed on macrophage-differentiated THP-1 cells at the highest tested concentration (1 mg/mL). Fucoidan microparticles also exhibited a propensity to be captured by macrophages in a dose-dependent manner, as well as an ability to activate the target cells. Furthermore, drug-loaded microparticles effectively inhibited mycobacterial growth in vitro. Thus, the produced fucoidan microparticles are considered to hold potential as pulmonary delivery systems for the treatment of tuberculosis.

show abstract

Section: Resultssupporting

confidence: 57%

Inhalable Fucoidan Microparticles Combining Two Antitubercular Drugs with Potential Application in Pulmonary Tuberculosis Therapy

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Other approaches to increase fine particle dose have recently been proposed, for example, the use of an add on accessory device to the DPI, the “Axial Oscillating Sphere” (Respira Therapeutics Inc.), which uses a small spherical bead oscillating in a cylindrical chamber to promote powder dispersion . Next to enhanced aerosol dispersion, it was shown in vitro to minimize flow rate dependency resulting in more consistent lung dosing.…”

Section: Discussionmentioning

confidence: 99%

Inspiromatic‐safety and efficacy study of a new generation dry powder inhaler in asthmatic children

Steuer

Prais

Mussaffi

et al. 2018

Pediatric Pulmonology

View full text Add to dashboard Cite

show abstract

“…In the past few years some new passive DPI have entered the market (in order of appearing in the market): NEXThaler ® , Ellipta ® , Forspiro ® or Zonda ® [15][16][17][18]. The new devices usually generate aerosols which have better parameters, normally practically independent from the patient's inspiratory flow but concurrently more patient-friendly in the everyday use compared with the previously appllied devices [19][20][21]. Ellipta ® is a good example of such an inhaler.…”

Section: Dry Powder Inhalersmentioning

confidence: 99%

Dry Powder Inhalers—Between the Doctor and the Patient

Emeryk

Pirożyński²,

Emeryk-Maksymiuk³

2018

Advances in Respiratory Medicine

View full text Add to dashboard Cite

The article briefly presents currently accessible dry powder inhalers (DPI). Basing on the data from the literature, we discussed the most common mistakes related to the utilisation of DPI as well as their clinical and economic consequences. We also extensively analysed all factors that may influence the efficacy and safety of inhaler therapy of asthma and COPD, mostly with the use of DPI. In addition, we indicated the potential to improve the efficacy of inhaler therapy from the doctor and COPD or asthma patient perspective. We also presented a DPI choice algorithm including the patient's preferences and competences.

show abstract

Accessorized DPI: a Shortcut towards Flexibility and Patient Adaptability in Dry Powder Inhalation

Abstract: Increasing inhaler performance can be achieved using an add-on accessory that enhances aerosol dispersion and minimizes flow rate dependency.

Cited by 12 publications

References 16 publications

Inhalable Fucoidan Microparticles Combining Two Antitubercular Drugs with Potential Application in Pulmonary Tuberculosis Therapy

Inhalable Fucoidan Microparticles Combining Two Antitubercular Drugs with Potential Application in Pulmonary Tuberculosis Therapy

Inspiromatic‐safety and efficacy study of a new generation dry powder inhaler in asthmatic children

Dry Powder Inhalers—Between the Doctor and the Patient

Contact Info

Product

Resources

About